Frankfurt - Delayed Quote EUR

Grifols, S.A. (G0F.F)

4.3600

0.0000

(0.00%)

As of 8:03:47 AM GMT+2. Market Open.

FDA clears Grifols’ application for dry eye disease treatment

The trial will assess the efficacy, safety, and tolerability of the treatment in 100 DED subjects.

Clinical Trials Arena yesterday

GRFS
GRFS or NBIX: Which Is the Better Value Stock Right Now?

GRFS vs. NBIX: Which Stock Is the Better Value Option?

Zacks 8 days ago

NBIX

GRFS
High Growth Tech Stocks in Europe for May 2025

As the pan-European STOXX Europe 600 Index continues its upward trajectory, marking a fourth consecutive week of gains amid easing trade tensions between China and the U.S., investors are closely watching how these developments influence high-growth tech stocks in Europe. In this dynamic environment, identifying promising tech stocks involves assessing their ability to innovate and adapt to shifting market conditions while leveraging opportunities presented by evolving trade relationships.

Simply Wall St. 9 days ago

GIFLF

GIFOF

GIKLY
Grifols reports Q1 adjusted EBITDA of EUR 400M, up 14.2% from last year

Net revenues reached EUR 1.786B, up 7.4% in constant currency. Like-for-like net revenues increased by 10.0% in constant currency. Adjusted EBITDA increased to EUR 400M, up 14.2% in constant currency and +21.7% on a constant currency, like-for-like basis. Nacho Abia, Chief Executive Officer, commented: “Building on our record-setting performances in 2023 and 2024, our first quarter clearly demonstrates continued momentum as we focus on executing our strategic plan. Healthy underlying demand in B

TipRanks 10 days ago

GIFLF

GIFOF

GIKLY
Grifols reaffirms guidance for 2025

Grifols (GRFS) said: “Grifols remains focused on the continued execution of its strategic plan and reaffirms its guidance for FY2025. Due to the impact of the Inflation Reduction Act on its financial results, Grifols expects to share greater detail in 2025 giving investors and analysts further visibility on its actual performance and underlying momentum. As a result, for 2025, Grifols expects to show both reported figures and LFL figures to make them comparable to previous quarters. LFL figures

TipRanks 10 days ago

GIFLF

GIFOF

GIKLY
Australia's CSL evaluates China tariff exemptions for its US-made drugs

SHANGHAI (Reuters) -Australia's CSL Ltd said it's evaluating whether its drugs used in surgery would be exempted from 125% tariffs China imposed on U.S.-made goods, as it seeks to minimise impact of a trade war between Beijing and Washington. China has granted tariff exemptions on select products, including select pharmaceuticals, and has also created a non-public list of goods that would be exempted from duties, Reuters reported earlier on Wednesday, in the clearest sign yet of Beijing's concerns about the trade war's fallout. The quiet approach allows Beijing, which has repeatedly said it is willing to fight until the end unless the U.S. lifts its 145% tariffs on Chinese imports, to maintain its public messaging while privately taking practical steps to provide concessions.

Reuters 23 days ago

CSL.AX

GRFS
Here’s White Falcon’s Views on Grifols, S.A. (GRFS)

White Falcon Capital Management, an investment fund manager, released its first-quarter 2025 investor letter. A copy of the letter can be downloaded here. The fund’s performance for the recent quarter was below expectations, as the gains from gold and silver royalty holdings were unable to cover the losses in some of the larger positions. On […]

Insider Monkey 25 days ago

GRFS

^GSPC
IBL partners with Grifols to develop biomarker panels for speciality diagnostics

The panels are being developed in response to customer feedback to meet lab and patient requirements.

Medical Device Network last month

GRFS
Exploring High Growth Tech Stocks In Europe April 2025

In recent weeks, European markets have experienced significant turbulence, with the pan-European STOXX Europe 600 Index dropping 8.44%, marking its steepest decline in five years amid heightened global trade tensions and uncertainty over U.S. tariff policies. As investors navigate this volatile environment, identifying high-growth tech stocks that can withstand economic headwinds becomes crucial; these stocks typically exhibit strong innovation capabilities, robust financial health, and...

Simply Wall St. last month

GIFLF

GIFOF

GIKLY
European Equities Close Lower in Wednesday Trading; Brookfield in Talks Again to Acquire Grifols

The European stock markets closed lower in Wednesday trading as The Stoxx Europe 600 fell 0.62%, Ger

PREMIUM
MT Newswires last month

GRFS

BAM

BHP
Spanish pharma company Grifols' shares up on Brookfield talk

MADRID (Reuters) -Shares in Spanish pharmaceutical company Grifols rose on Wednesday after Canadian fund Brookfield said it was talking with shareholders, following a report from website El Confidencial that it was considering a new takeover attempt. In a filing to the Madrid stock market regulator, Brookfield, however, said that it was not in talks with the company's board over a potential takeover bid. Grifols shares were up 4.4% at 8.49 euros ($9.18) after gaining 12% earlier in the day.

Reuters last month

GRFS
High Growth Tech Stocks in Europe for March 2025

As European markets face uncertainty due to U.S. trade policy and recent ECB rate cuts, the pan-European STOXX Europe 600 Index has snapped a 10-week streak of gains, although increased defense and infrastructure spending in Germany and the EU have helped mitigate losses. In this environment, identifying high growth tech stocks involves looking for companies that can leverage innovation to navigate economic challenges and capitalize on shifts in consumer behavior or government spending...

Simply Wall St. 2 months ago

GIFLF

GIFOF

GIKLY
Is Grifols, S.A. (GRFS) the Best Low Price Pharma Stock to Invest In Right Now?

We recently compiled a list of the 12 Best Low Price Pharma Stocks To Invest In Right Now. In this article, we are going to take a look at where Grifols, S.A. (NASDAQ:GRFS) stands against the other pharma stocks. The Rising Demand for Weight-Loss Medications and GLP-1 Developments Healthcare, which includes numerous businesses that offer patient […]

Insider Monkey 2 months ago

GRFS
Grifols SA (GIFLF) (Q4 2024) Earnings Call Highlights: Record Revenues and Strategic ...

Grifols SA (GIFLF) reports robust growth in its biopharma segment and significant balance sheet improvements, despite facing currency and margin pressures.

GuruFocus.com 2 months ago

GRFS
Exploring High Growth Tech Stocks In February 2025

As global markets navigate a volatile start to 2025, with the Federal Reserve holding rates steady and AI competition shaking up the tech sector, investors are closely watching how these dynamics impact high-growth opportunities. In this climate of rapid technological advancements and shifting economic indicators, identifying promising tech stocks involves assessing their innovation potential and resilience in adapting to emerging challenges like those posed by new AI developments.

Simply Wall St. 3 months ago

GIFLF

GIFOF

GIKLY
Grifols Pioneers High-Tech Analysis of Plasma Bank to Detect Early Signs of Parkinson’s Disease

‘Chronos-PD’ is looking for biological signals that could indicate increased chance of developing Parkinson’s disease (PD) years before symptoms appear, leading to new diagnostic tools and disease-modifying therapiesPart of broad Grifols program to find disease-revealing clues in more than 100 million proprietary plasma samples connected to real-world data on thousands of disease states in many therapeutic areasCutting-edge use of AI and proteomics technology paired with real-world evidence unde

GlobeNewswire 4 months ago

GIFLF

GIFOF

GIKLY
Mason Capital complains about Grifols' transparency to Spanish regulator

U.S.-based investment fund Mason Capital said on Monday it had sent a letter to Spain's stock market regulator CNMV demanding more transparency from the embattled pharmaceutical company Grifols. The activist fund said in a statement it had identified potential conflicts of interest linked to related party transactions by current board members, failure of internal controls and a "rumoured clause" in a recent bond issuance that benefits Canadian fund Brookfield at shareholders' expense. "We urge the CNMV to consider the benefits to all Grifols shareholders from improved disclosure," Mason Capital said.

Reuters 4 months ago

GRFS
Exploring Three High Growth Tech Stocks For Future Potential

As global markets navigate a mixed economic landscape marked by declining consumer confidence and fluctuating indices, technology stocks continue to capture attention with their potential for high growth. In this environment, identifying promising tech stocks involves assessing factors such as innovation, market demand, and the ability to adapt to changing economic conditions.

Simply Wall St. 4 months ago

GIFLF

GIFOF

GIKLY
Exploring High Growth Tech Stocks This December 2024

As global markets reach new heights, with indices like the Russell 2000 hitting record intraday highs, investor sentiment remains buoyed by domestic policy developments and easing geopolitical tensions. In this environment, identifying high-growth tech stocks that can capitalize on current economic trends and technological advancements is crucial for investors seeking to navigate the evolving landscape of December 2024.

Simply Wall St. 5 months ago

GIFLF

GIFOF

GIKLY
Sector Update: Health Care Stocks Slipping Late Afternoon

Health care stocks were easing late Monday afternoon, with the NYSE Health Care Index and the Health

PREMIUM
MT Newswires 5 months ago

PTCT

SNTI

NVS

Performance Overview

Return	G0F.F	IBEX 35... (^IBEX)
YTD	+1.87%	+22.25%
1-Year	-1.36%	+24.69%
3-Year	-54.35%	+63.51%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

Grifols, S.A. (G0F.F)

FDA clears Grifols’ application for dry eye disease treatment

GRFS or NBIX: Which Is the Better Value Stock Right Now?

High Growth Tech Stocks in Europe for May 2025

Grifols reports Q1 adjusted EBITDA of EUR 400M, up 14.2% from last year

Grifols reaffirms guidance for 2025

Australia's CSL evaluates China tariff exemptions for its US-made drugs

Here’s White Falcon’s Views on Grifols, S.A. (GRFS)

IBL partners with Grifols to develop biomarker panels for speciality diagnostics

Exploring High Growth Tech Stocks In Europe April 2025

European Equities Close Lower in Wednesday Trading; Brookfield in Talks Again to Acquire Grifols

Spanish pharma company Grifols' shares up on Brookfield talk

High Growth Tech Stocks in Europe for March 2025

Is Grifols, S.A. (GRFS) the Best Low Price Pharma Stock to Invest In Right Now?

Grifols SA (GIFLF) (Q4 2024) Earnings Call Highlights: Record Revenues and Strategic ...

Exploring High Growth Tech Stocks In February 2025

Grifols Pioneers High-Tech Analysis of Plasma Bank to Detect Early Signs of Parkinson’s Disease

Mason Capital complains about Grifols' transparency to Spanish regulator

Exploring Three High Growth Tech Stocks For Future Potential

Exploring High Growth Tech Stocks This December 2024

Sector Update: Health Care Stocks Slipping Late Afternoon

Performance Overview